Gabelli Downgrades Nabriva Therapeutics AG (NBRV) to Sell

Gabelli analyst Kevin Kedra downgraded Nabriva Therapeutics AG (NASDAQ: NBRV) from Hold to Sell with a price target of $2.00.

The analyst comments "Our decision to lower our recommendation to Sell is a reflection of NBRV’s current valuation relative to near-term risks. We note that the company’s market capitalization is ahead of several peers with one or more approved antibiotics. We continue to believe that the antibiotic sector is broadly undervalued when taking a long-term view, but we cannot ignore the current market dynamics and near-term risk factors. The risk/reward balance for Nabriva heading into the April 30 PDUFA for Contepo tilts heavily toward the negative as shares trade at a significant premium to our 2020 riskadjusted PMV of $2.00 per share."

For an analyst ratings summary and ratings history on Nabriva Therapeutics AG click here. For more ratings news on Nabriva Therapeutics AG click here.

Shares of Nabriva Therapeutics AG closed at $2.73 yesterday.

You May Also Be Interested In

• Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
• Duos Technologies Group (DUOT) PT Raised to $27 at Cantor Fitzgerald on 'Extremely Attractive' Risk/Reward
• Compass Point Upgrades Strawberry Fields REIT (STRW) to Buy